The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses

Nutrients

Volumn 5, Issue 6, 2013, Pages 2231-2257

  Soliman, Ghada A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Adaptive immunity; B cells; Immunosuppression; Innate immunity; mTOR; mTORC1; mTORC2; Rapamycin; Regulatory T cells; T helper

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EVEROLIMUS; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RIDAFOROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CARBOHYDRATE METABOLISM; CELLULAR IMMUNITY; CLONAL ANERGY; COMPLEX FORMATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EFFECTOR CELL; HELPER CELL; HUMAN; HUMORAL IMMUNITY; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LIPID METABOLISM; LYMPHOCYTE DIFFERENTIATION; MALIGNANT NEOPLASTIC DISEASE; MEMORY CELL; METABOLIC REGULATION; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; WOUND HEALING IMPAIRMENT;

EID: 84879304000     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5062231     Document Type: Review

References (196)

1. Soliman, G.A. The integral role of mTOR in lipid metabolism. Cell Cycle 2011, 10, 861-862.
2. Laplante, M.; Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122, 3589-3594.
3. Howell, J.J.; Manning, B.D. mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol. Metab. 2011, 22, 94-102.
4. Yecies, J.L.; Manning, B.D. mTOR links oncogenic signaling to tumor cell metabolism. J. Mol. Med. 2011, 89, 221-228.
5. Soliman, G.A. The mammalian target of rapamycin signaling network and gene regulation. Curr. Opin. Lipidol. 2005, 16, 317-323.
6. Foster, K.G.; Fingar, D.C. Mammalian target of rapamycin (mTOR): Conducting the cellular signaling symphony. J. Biol. Chem. 2010, 285, 14071-14077.
7. Stan, R.; McLaughlin, M.M.; Cafferkey, R.; Johnson, R.K.; Rosenberg, M.; Livi, G.P. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J. Biol. Chem. 1994, 269, 32027-32030.
8. Cafferkey, R.; McLaughlin, M.M.; Young, P.R.; Johnson, R.K.; Livi, G.P. Yeast TOR (DRR) proteins: Amino-acid sequence alignment and identification of structural motifs. Gene 1994, 141, 133-136.
9. Stewart, M.J.; Berry, C.O.; Zilberman, F.; Thomas, G.; Kozma, S.C. The Drosophila p70s6k homolog exhibits conserved regulatory elements and rapamycin sensitivity. Proc. Natl. Acad. Sci. USA 1996, 93, 10791-10796.
10. Polak, P.; Hall, M.N. mTORC2 caught in a SINful Akt. Dev. Cell 2006, 11, 433-434.
11. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell 2006, 124, 471-484.
12. Corradetti, M.N.; Guan, K.L. Upstream of the mammalian target of rapamycin: Do all roads pass through mTOR? Oncogene 2006, 25, 6347-6360.
13. Staschke, K.A.; Dey, S.; Zaborske, J.M.; Palam, L.R.; McClintick, J.N.; Pan, T.; Edenberg, H.J.; Wek, R.C. Integration of general amino acid control and target of rapamycin (TOR) regulatory pathways in nitrogen assimilation in yeast. J. Biol. Chem. 2010, 285, 16893-16911.
14. Schmidt, A.; Beck, T.; Koller, A.; Kunz, J.; Hall, M.N. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease. EMBO J. 1998, 17, 6924-6931.
15. Laplante, M.; Sabatini, D.M. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009, 19, R1046-R1052.
16. Duvel, K.; Yecies, J.L.; Menon, S.; Raman, P.; Lipovsky, A.I.; Souza, A.L.; Triantafellow, E.; Ma, Q.; Gorski, R.; Cleaver, S. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39, 171-183.
17. McMahon, G.; Weir, M.R.; Li, X.C.; Mandelbrot, D.A. The evolving role of mTOR inhibition in transplantation tolerance. J. Am. Soc. Nephrol. 2011, 22, 408-415.
18. Reidy-Lagunes, D.; Thornton, R. Pancreatic neuroendocrine and carcinoid tumors: What's new, what's old, and what's different? Curr. Oncol. Rep. 2012, 14, 249-256.
19. Arva, N.C.; Pappas, J.G.; Bhatla, T.; Raetz, E.A.; Macari, M.; Ginsburg, H.B.; Hajdu, C.H. Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis--Case report and review of the literature. Am. J. Surg. Pathol. 2012, 36, 149-153.
20. Aggarwal, D.; Fernandez, M.L.; Soliman, G.A. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. Metab. Clin. Exp. 2006, 55, 794-802.
21. Chakrabarti, P.; English, T.; Shi, J.; Smas, C.M.; Kandror, K.V. Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. Diabetes 2010, 59, 775-781.
22. Ogmundsdottir, M.H.; Heublein, S.; Kazi, S.; Reynolds, B.; Visvalingam, S.M.; Shaw, M.K.; Goberdhan, D.C. Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes. PLoS One 2012, 7, e36616, doi:10.1371/journal.pone.0036616.
23. Cang, C.; Zhou, Y.; Navarro, B.; Seo, Y.J.; Aranda, K.; Shi, L.; Battaglia-Hsu, S.; Nissim, I.; Clapham, D.E.; Ren, D. mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state. Cell 2013, 152, 778-790.
24. Powell, J.D.; Pollizzi, K.N.; Heikamp, E.B.; Horton, M.R. Regulation of immune responses by mTOR. Ann. Rev. Immunol. 2012, 30, 39-68.
25. Colombetti, S.; Basso, V.; Mueller, D.L.; Mondino, A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 2006, 176, 2730-2738.
26. Powell, J.D.; Delgoffe, G.M. The mammalian target of rapamycin: Linking T cell differentiation, function, and metabolism. Immunity 2010, 33, 301-311.
27. Rao, R.R.; Li, Q.; Odunsi, K.; Shrikant, P.A. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010, 32, 67-78.
28. Rao, R.R.; Li, Q.; Shrikant, P.A. Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation? Cell Cycle 2010, 9, 2996-3001.
29. Gulen, M.F.; Kang, Z.; Bulek, K.; Youzhong, W.; Kim, T.W.; Chen, Y.; Altuntas, C.Z.; Sass Bak-Jensen, K.; McGeachy, M.J.; Do, J.S. et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010, 32, 54-66.
30. Xiao, H.; Yin, W.; Khan, M.A.; Gulen, M.F.; Zhou, H.; Sham, H.P.; Jacobson, K.; Vallance, B.A.; Li, X. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 2010, 139, 574-585.
31. Garami, A.; Zwartkruis, F.J.; Nobukuni, T.; Joaquin, M.; Roccio, M.; Stocker, H.; Kozma, S.C.; Hafen, E.; Bos, J.L.; Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 2003, 11, 1457-1466.
32. Stocker, H.; Radimerski, T.; Schindelholz, B.; Wittwer, F.; Belawat, P.; Daram, P.; Breuer, S.; Thomas, G.; Hafen, E. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol. 2003, 5, 559-565.
33. Nobukini, T.; Thomas, G. The mTOR/S6K signalling pathway: The role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found. Symp. 2004, 262, 148-154; discussion 154-149, 265-148.
34. Kwiatkowski, D.J.; Zhang, H.; Bandura, J.L.; Heiberger, K.M.; Glogauer, M.; el-Hashemite, N.; Onda, H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 2002, 11, 525-534.
35. Kwiatkowski, D.J.; Manning, B.D. Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum. Mol. Genet. 2005, 14, R251-R258.
36. Inoki, K.; Ouyang, H.; Zhu, T.; Lindvall, C.; Wang, Y.; Zhang, X.; Yang, Q.; Bennett, C.; Harada, Y.; Stankunas, K. et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126, 955-968.
37. Yoshida, S.; Hong, S.; Suzuki, T.; Nada, S.; Mannan, A.M.; Wang, J.; Okada, M.; Guan, K.L.; Inoki, K. Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J. Biol. Chem. 2011, 286, 32651-32660.
38. Yang, Q.; Inoki, K.; Kim, E.; Guan, K.L. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proc. Natl. Acad. Sci. USA 2006, 103, 6811-6816.
39. Um, S.H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; Allegrini, P.R.; Kozma, S.C.; Auwerx, J. et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431, 200-205.
40. Peterson, T.R.; Sengupta, S.S.; Harris, T.E.; Carmack, A.E.; Kang, S.A.; Balderas, E.; Guertin, D.A.; Madden, K.L.; Carpenter, A.E.; Finck, B.N. et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146, 408-420.
41. Kim, S.G.; Hoffman, G R.; Poulogiannis, G.; Buel, G.R.; Jang, Y.J.; Lee, K.W.; Kim, B.Y.; Erikson, R.L.; Cantley, L.C.; Choo, A.Y. et al. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol. Cell 2013, 49, 172-185.
42. Sparks, C.A.; Guertin, D.A. Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29, 3733-3744.
43. Hresko, R.C.; Mueckler, M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280, 40406-40416.
44. Yecies, J.L.; Manning, B.D. Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 2011, 71, 2815-2820.
45. Cantor, J.R.; Sabatini, D.M. Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2012, 2, 881-898.
46. Warburg, O. The effect of hydrogen peroxide on cancer cells and on embryonic cells. Acta Unio Int. Contra Cancrum 1958, 14, 55-57.
47. Zheng, Y.; Delgoffe, G.M.; Meyer, C.F.; Chan, W.; Powell, J.D. Anergic T cells are metabolically anergic. J. Immunol. 2009, 183, 6095-6101.
48. Delgoffe, G.M.; Powell, J.D. mTOR: Taking cues from the immune microenvironment. Immunology 2009, 127, 459-465.
49. Powell, J.D.; Lerner, C.G.; Schwartz, R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 1999, 162, 2775-2784.
50. Allen, A.; Zheng, Y.; Gardner, L.; Safford, M.; Horton, M.R.; Powell, J.D. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J. Immunol. 2004, 172, 4797-4803.
51. Vanasek, T.L.; Khoruts, A.; Zell, T.; Mueller, D.L. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: Enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 2001, 167, 5636-5644.
52. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18, 1926-1945.
53. Lekmine, F.; Uddin, S.; Sassano, A.; Parmar, S.; Brachmann, S.M.; Majchrzak, B.; Sonenberg, N.; Hay, N.; Fish, E.N.; Platanias, L.C. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 2003, 278, 27772-27780.
54. Gingras, A.C.; Kennedy, S.G.; O'Leary, M.A.; Sonenberg, N.; Hay, N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12, 502-513.
55. Fingar, D.C.; Richardson, C.J.; Tee, A.R.; Cheatham, L.; Tsou, C.; Blenis, J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2004, 24, 200-216.
56. Fingar, D.C.; Blenis, J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23, 3151-3171.
57. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11, 859-871.
58. Lazorchak, A.S.; Su, B. Perspectives on the role of mTORC2 in B lymphocyte development, immunity and tumorigenesis. Protein Cell 2011, 2, 523-530.
59. Yuan, M.; Pino, E.; Wu, L.; Kacergis, M.; Soukas, A.A. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J. Biol. Chem. 2012, 287, 29579-29588.
60. Mayer, C.; Grummt, I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006, 25, 6384-6391.
61. White, R.J.; Sharrocks, A.D. Coordinated control of the gene expression machinery. Trends Genet 2010, 26, 214-220.
62. Gingras, A.C.; Raught, B.; Sonenberg, N. mTOR signaling to translation. Curr. Top. Microbiol. Immunol. 2004, 279, 169-197.
63. Proud, C.G. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr. Top. Microbiol. Immunol. 2004, 279, 215-244.
64. Proud, C.G. The multifaceted role of mTOR in cellular stress responses. DNA Repair 2004, 3, 927-934.
65. Desvergne, B.; Michalik, L.; Wahli, W. Transcriptional regulation of metabolism. Physiol. Rev. 2006, 86, 465-514.
66. Lian, J.; Yan, X.H.; Peng, J.; Jiang, S.W. The mammalian target of rapamycin pathway and its role in molecular nutrition regulation. Mol. Nutr. Food Res. 2008, 52, 393-399.
67. Peng, T.; Golub, T.R.; Sabatini, D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol. 2002, 22, 5575-5584.
68. Brown, N.F.; Stefanovic-Racic, M.; Sipula, I.J.; Perdomo, G. The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. Metabolism 2007, 56, 1500-1507.
69. Porstmann, T.; Santos, C.R.; Griffiths, B.; Cully, M.; Wu, M.; Leevers, S.; Griffiths, J.R.; Chung, Y.L.; Schulze, A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8, 224-236.
70. Mauvoisin, D.; Rocque, G.; Arfa, O.; Radenne, A.; Boissier, P.; Mounier, C. Role of thePI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J. Cell Commun. Signal. 2007, 1, 113-125.
71. Kumar, A.; Lawrence, J.C., Jr.; Jung, D.Y.; Ko, H.J.; Keller, S.R.; Kim, J.K.; Magnuson, M.A.; Harris, T.E. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010, 59, 1397-1406.
72. Meijer, A.J.; Codogno, P. Regulation and role of autophagy in mammalian cells. Int. J. Biochem. Cell Biol. 2004, 36, 2445-2462.
73. Iwamaru, A.; Kondo, Y.; Iwado, E.; Aoki, H.; Fujiwara, K.; Yokoyama, T.; Mills, G.B.; Kondo, S. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007, 26, 1840-1851.
74. Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414, 799-806.
75. Zhong, H.; Chiles, K.; Feldser, D.; Laughner, E.; Hanrahan, C.; Georgescu, M.M.; Simons, J.W.; Semenza, G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60, 1541-1545.
76. Hudson, C.C.; Liu, M.; Chiang, G.G.; Otterness, D.M.; Loomis, D.C.; Kaper, F.; Giaccia, A.J.; Abraham, R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 2002, 22, 7004-7014.
77. Hu, C.J.; Wang, L.Y.; Chodosh, L.A.; Keith, B.; Simon, M.C. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23, 9361-9374.
78. Liu, H.; Remedi, M.S.; Pappan, K.L.; Kwon, G.; Rohatgi, N.; Marshall, C.A.; McDaniel, M.L. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. Diabetes 2009, 58, 663-672.
79. Wagle, A.; Jivraj, S.; Garlock, G.L.; Stapleton, S.R. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J. Biol. Chem. 1998, 273, 14968-14974.
80. Dunlop, E.A.; Tee, A.R. Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cell Signal. 2009, 21, 827-835.
81. Vila-Bedmar, R.; Lorenzo, M.; Fernandez-Veledo, S. Adenosine 5′-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differentiation. Endocrinology 2010, 151, 980-992.
82. Ekim, B.; Magnuson, B.; Acosta-Jaquez, H.A.; Keller, J.A.; Feener, E.P.; Fingar, D.C. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol. Cell. Biol. 2011, 31, 2787-2801.
83. Festuccia, W.T.; Laplante, M.; Brule, S.; Houde, V.P.; Achouba, A.; Lachance, D.; Pedrosa, M.L.; Silva, M.E.; Guerra-Sa, R.; Couet, J. et al. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J. Mol. Cell. Cardiol. 2009, 47, 85-95.
84. Powers, T. Cell growth control: mTOR takes on fat. Mol. Cell 2008, 31, 775-776.
85. Soliman, G.A.; Acosta-Jaquez, H.A.; Fingar, D.C. mTORC1 inhibition via rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes. Lipids 2010, 45, 1089-1100.
86. Fraenkel, M.; Ketzinel-Gilad, M.; Ariav, Y.; Pappo, O.; Karaca, M.; Castel, J.; Berthault, M.F.; Magnan, C.; Cerasi, E.; Kaiser, N. et al. mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57, 945-957.
87. Leibowitz, G.; Kaiser, N.; Cerasi, E. Balancing needs and means: The dilemma of the beta-cell in the modern world. Diabetes Obes. Metab. 2009, 11 (Suppl. 4), 1-9.
88. Kimball, S.R. Regulation of translation initiation by amino acids in eukaryotic cells. Prog. Mol. Subcell Biol. 2001, 26, 155-184.
89. Roh, C.; Han, J.; Tzatsos, A.; Kandror, K.V. Nutrient-sensing mTOR-mediated pathway regulates leptin production in isolated rat adipocytes. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E322-E330.
90. Tokunaga, C.; Yoshino, K.; Yonezawa, K. mTOR integrates amino acid-and energy-sensing pathways. Biochem. Biophys. Res. Commun. 2004, 313, 443-446.
91. Kim, D.H.; Sabatini, D.M. Raptor and mTOR: Subunits of a nutrient-sensitive complex. Curr. Top. Microbiol. Immunol. 2004, 279, 259-270.
92. Kimball, S.R.; Jefferson, L.S. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of rapamycin. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7, 39-44.
93. Matsumura, T.; Morinaga, Y.; Fujitani, S.; Takehana, K.; Nishitani, S.; Sonaka, I. Oral administration of branched-chain amino acids activates the mTOR signal in cirrhotic rat liver. Hepatol. Res. 2005, 33, 27-32.
94. Nishitani, S.; Ijichi, C.; Takehana, K.; Fujitani, S.; Sonaka, I. Pharmacological activities of branched-chain amino acids: Specificity of tissue and signal transduction. Biochem. Biophys. Res. Commun. 2004, 313, 387-389.
95. Roscic, A.; Baldo, B.; Crochemore, C.; Marcellin, D.; Paganetti, P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 2011, 119, 398-407.
96. Delves, P.J.; Maitin, S.; Burton, D.R.; Roitt, I.M. Roitt's Essential Immunology, 12th ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2011.
97. Chi, H. Regulation and function of mTOR signalling in T cell fate decisions. Nat. Rev. Immunol. 2012, 12, 325-338.
98. Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327, 291-295.
99. Haidinger, M.; Poglitsch, M.; Geyeregger, R.; Kasturi, S.; Zeyda, M.; Zlabinger, G.J.; Pulendran, B.; Horl, W.H.; Saemann, M.D.; Weichhart, T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J. Immunol. 2010, 185, 3919-3931.
100. Katholnig, K.; Kaltenecker, C.C.; Hayakawa, H.; Rosner, M.; Lassnig, C.; Zlabinger, G.J.; Gaestel, M.; Muller, M.; Hengstschlager, M.; Horl, W.H. et al. p38alpha senses environmental stress to control innate immune responses via mechanistic target of rapamycin. J. Immunol. 2013, 190, 1519-1527.
101. Haidinger, M.; Werzowa, J.; Weichhart, T.; Saemann, M.D. Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: Killing 2 birds with 1 stone. Transplant. Rev. 2011, 25, 145-153.
102. Saemann, M.D.; Haidinger, M.; Hecking, M.; Horl, W.H.; Weichhart, T. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am. J. Transplant. 2009, 9, 2655-2661.
103. Weichhart, T.; Saemann, M.D. The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67 (Suppl. 3), 370-374.
104. Hackstein, H.; Taner, T.; Zahorchak, A.F.; Morelli, A.E.; Logar, A.J.; Gessner, A.; Thomson, A.W. Rapamycin inhibits IL-4--Induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101, 4457-4463.
105. Hackstein, H.; Taner, T.; Logar, A.J.; Thomson, A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100, 1084-1087.
106. Monti, P.; Mercalli, A.; Leone, B.E.; Valerio, D.C.; Allavena, P.; Piemonti, L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75, 137-145.
107. Sathaliyawala, T.; O'Gorman, W.E.; Greter, M.; Bogunovic, M.; Konjufca, V.; Hou, Z.E.; Nolan, G.P.; Miller, M.J.; Merad, M.; Reizis, B. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010, 33, 597-606.
108. Turnquist, H.R.; Raimondi, G.; Zahorchak, A.F.; Fischer, R.T.; Wang, Z.; Thomson, A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 2007, 178, 7018-7031.
109. Ohtani, M.; Hoshii, T.; Fujii, H.; Koyasu, S.; Hirao, A.; Matsuda, S. Cutting edge: mTORC1 in intestinal CD11c+ CD11b+ dendritic cells regulates intestinal homeostasis by promoting IL-10 production. J. Immunol. 2012, 188, 4736-4740.
110. Weichhart, T.; Costantino, G.; Poglitsch, M.; Rosner, M.; Zeyda, M.; Stuhlmeier, K.M.; Kolbe, T.; Stulnig, T.M.; Horl, W.H.; Hengstschlager, M. et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29, 565-577.
111. Neudoerfl, C.; Mueller, B.J.; Blume, C.; Daemen, K.; Stevanovic-Meyer, M.; Keil, J.; Lehner, F.; Haller, H.; Falk, C.S. The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front. Immunol. 2013, 4, 46, doi:10.3389/fimmu.2013.00046.
112. Weichhart, T. Mammalian target of rapamycin: A signaling kinase for every aspect of cellular life. Methods Mol. Biol. 2012, 821, 1-14.
113. Thomson, A.W.; Turnquist, H.R.; Raimondi, G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol. 2009, 9, 324-337.
114. Rosborough, B.R.; Raich-Regue, D.; Matta, B.M.; Lee, K.; Gan, B.; Depinho, R.A.; Hackstein, H.; Boothby, M.; Turnquist, H.R.; Thomson, A.W. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1 and regulatory T cell induction. Blood 2013, doi:10.1182/blood-2012-08-448290.
115. Schmitz, F.; Heit, A.; Dreher, S.; Eisenacher, K.; Mages, J.; Haas, T.; Krug, A.; Janssen, K.P.; Kirschning, C.J.; Wagner, H. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur. J. Immunol. 2008, 38, 2981-2992.
116. Kirsch, A.H.; Riegelbauer, V.; Tagwerker, A.; Rudnicki, M.; Rosenkranz, A.R.; Eller, K. The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. Am. J. Physiol. Ren. Physiol. 2012, 303, F569-F575.
117. Wicker, L.S.; Boltz, R.C., Jr.; Matt, V.; Nichols, E.A.; Peterson, L.B.; Sigal, N.H. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur. J. Immunol. 1990, 20, 2277-2283.
118. Kay, J.E.; Kromwel, L.; Doe, S.E.; Denyer, M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991, 72, 544-549.
119. Aagaard-Tillery, K.M.; Jelinek, D.F. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell. Immunol. 1994, 156, 493-507.
120. Sakata, A.; Kuwahara, K.; Ohmura, T.; Inui, S.; Sakaguchi, N. Involvement of a rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro. Immunol. Lett. 1999, 68, 301-309.
121. Donahue, A.C.; Fruman, D.A. Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. Eur. J. Immunol. 2007, 37, 2923-2936.
122. Zhang, S.; Readinger, J.A.; DuBois, W.; Janka-Junttila, M.; Robinson, R.; Pruitt, M.; Bliskovsky, V.; Wu, J.Z.; Sakakibara, K.; Patel, J. et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood 2011, 117, 1228-1238.
123. Benhamron, S.; Tirosh, B. Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells. Eur. J. Immunol. 2011, 41, 2390-2396.
124. Llorian, M.; Stamataki, Z.; Hill, S.; Turner, M.; Martensson, I.L. The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J. Immunol. 2007, 178, 1981-1985.
125. Donahue, A.C.; Fruman, D.A. Proliferation and survival of activated B cells requires sustained antigen receptor engagement and phosphoinositide 3-kinase activation. J. Immunol. 2003, 170, 5851-5860.
126. Hess, K.L.; Donahue, A.C.; Ng, K.L.; Moore, T.I.; Oak, J.; Fruman, D.A. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. Eur. J. Immunol. 2004, 34, 2968-2976.
127. Goldfinger, M.; Shmuel, M.; Benhamron, S.; Tirosh, B. Protein synthesis in plasma cells is regulated by crosstalk between endoplasmic reticulum stress and mTOR signaling. Eur. J. Immunol. 2011, 41, 491-502.
128. Waickman, A.T.; Powell, J.D. Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J. Immunol. 2012, 188, 4721-4729.
129. Katzman, S.D.; O'Gorman, W.E.; Villarino, A.V.; Gallo, E.; Friedman, R.S.; Krummel, M.F.; Nolan, G.P.; Abbas, A.K. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc. Natl. Acad. Sci. USA 2010, 107, 18085-18090.
130. Hackstein, H. Rapamycin and dendritic cells: Keep on movin'. Transplantation 2006, 82, 739-740.
131. Yang, K.; Neale, G.; Green, D.R.; He, W.; Chi, H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat. Immunol. 2011, 12, 888-897.
132. Zhang, L.; Zhang, H.; Li, L.; Xiao, Y.; Rao, E.; Miao, Z.; Chen, H.; Sun, L.; Li, H.; Liu, G. et al. TSC1/2 signaling complex is essential for peripheral naive CD8+ T cell survival and homeostasis in mice. PLoS One 2012, 7, e30592, doi:10.1371/journal.pone.0030592.
133. Gao, N.; Zhang, Z.; Jiang, B.H.; Shi, X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 2003, 310, 1124-1132.
134. Gao, N.; Flynn, D.C.; Zhang, Z.; Zhong, X.S.; Walker, V.; Liu, K.J.; Shi, X.; Jiang, B.H. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am. J. Physiol. Cell Physiol. 2004, 287, C281-C291.
135. Jones, R.G.; Thompson, C.B. Revving the engine: Signal transduction fuels T cell activation. Immunity 2007, 27, 173-178.
136. De Zoeten, E.F.; Lee, I.; Wang, L.; Chen, C.; Ge, G.; Wells, A.D.; Hancock, W.W.; Ozkaynak, E. Foxp3 processing by proprotein convertases and control of regulatory T cell function. J. Biol. Chem. 2009, 284, 5709-5716.
137. Mercer, F.; Unutmaz, D. The biology of FoxP3: A key player in immune suppression during infections, autoimmune diseases and cancer. Adv. Exp. Med. Biol. 2009, 665, 47-59.
138. Battaglia, M.; Stabilini, A.; Roncarolo, M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105, 4743-4748.
139. Battaglia, M.; Stabilini, A.; Migliavacca, B.; Horejs-Hoeck, J.; Kaupper, T.; Roncarolo, M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006, 177, 8338-8347.
140. Monti, P.; Scirpoli, M.; Maffi, P.; Piemonti, L.; Secchi, A.; Bonifacio, E.; Roncarolo, M.G.; Battaglia, M. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57, 2341-2347.
141. Kang, J.; Huddleston, S.J.; Fraser, J.M.; Khoruts, A. De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J. Leukoc. Biol. 2008, 83, 1230-1239.
142. Kopf, H.; de la Rosa, G.M.; Howard, O.M.; Chen, X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int. Immunopharmacol. 2007, 7, 1819-1824.
143. Zeiser, R.; Leveson-Gower, D.B.; Zambricki, E.A.; Kambham, N.; Beilhack, A.; Loh, J.; Hou, J.Z.; Negrin, R.S. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111, 453-462.
144. Delgoffe, G.M.; Pollizzi, K.N.; Waickman, A.T.; Heikamp, E.; Meyers, D.J.; Horton, M.R.; Xiao, B.; Worley, P.F.; Powell, J.D. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12, 295-303.
145. Shi, L.Z.; Wang, R.; Huang, G.; Vogel, P.; Neale, G.; Green, D.R.; Chi, H. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011, 208, 1367-1376.
146. Liu, Q.; Xu, C.; Kirubakaran, S.; Zhang, X.; Hur, W.; Liu, Y.; Kwiatkowski, N.P.; Wang, J.; Westover, K.D.; Gao, P. et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR. Cancer Res. 2013, 73, 2574-2586.
147. Cobbold, S.P.; Adams, E.; Farquhar, C.A.; Nolan, K.F.; Howie, D.; Lui, K.O.; Fairchild, P.J.; Mellor, A.L.; Ron, D.; Waldmann, H. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl. Acad. Sci. USA 2009, 106, 12055-12060.
148. Peter, C.; Waldmann, H.; Cobbold, S.P. mTOR signalling and metabolic regulation of T cell differentiation. Curr. Opin. Immunol. 2010, 22, 655-661.
149. Merkenschlager, M.; von Boehmer, H. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J. Exp. Med. 2010, 207, 1347-1350.
150. Sauer, S.; Bruno, L.; Hertweck, A.; Finlay, D.; Leleu, M.; Spivakov, M.; Knight, Z.A.; Cobb, B.S.; Cantrell, D.; O'Connor, E. et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 2008, 105, 7797-7802.
151. Delgoffe, G.M.; Kole, T.P.; Zheng, Y.; Zarek, P.E.; Matthews, K.L.; Xiao, B.; Worley, P.F.; Kozma, S.C.; Powell, J.D. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30, 832-844.
152. Waickman, A.T.; Powell, J.D. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 2012, 249, 43-58.
153. Lee, K.; Gudapati, P.; Dragovic, S.; Spencer, C.; Joyce, S.; Killeen, N.; Magnuson, M.A.; Boothby, M. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32, 743-753.
154. Delgoffe, G.M.; Powell, J.D. Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes. Methods Mol. Biol. 2012, 821, 317-327.
155. Yamada, T.; Gierach, K.; Lee, P.H.; Wang, X.; Lacorazza, H.D. Cutting edge: Expression of the transcription factor E74-like factor 4 is regulated by the mammalian target of rapamycin pathway in CD8+ T cells. J. Immunol. 2010, 185, 3824-3828.
156. Araki, K.; Youngblood, B.; Ahmed, R. The role of mTOR in memory CD8 T-cell differentiation. Immunol. Rev. 2010, 235, 234-243.
157. Li, Q.; Rao, R.R.; Araki, K.; Pollizzi, K.; Odunsi, K.; Powell, J.D.; Shrikant, P.A. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity 2011, 34, 541-553.
158. Finlay, D.K. mTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB. Biochem. Soc. Trans. 2013, 41, 681-686.
159. Finlay, D.; Cantrell, D. Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration. Ann. N. Y. Acad. Sci. 2010, 1183, 149-157.
160. Finlay, D.K.; Rosenzweig, E.; Sinclair, L.V.; Feijoo-Carnero, C.; Hukelmann, J.L.; Rolf, J.; Panteleyev, A.A.; Okkenhaug, K.; Cantrell, D.A. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 2012, 209, 2441-2453.
161. Kurebayashi, Y.; Nagai, S.; Ikejiri, A.; Koyasu, S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells Devoted Mol. Cell. Mech. 2013, 18, 247-265.
162. Ikejiri, A.; Nagai, S.; Goda, N.; Kurebayashi, Y.; Osada-Oka, M.; Takubo, K.; Suda, T.; Koyasu, S. Dynamic regulation of Th17 differentiation by oxygen concentrations. Int. Immunol. 2012, 24, 137-146.
163. Sengupta, S.; Peterson, T.R.; Sabatini, D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 2010, 40, 310-322.
164. Majumder, P.K.; Febbo, P.G.; Bikoff, R.; Berger, R.; Xue, Q.; McMahon, L.M.; Manola, J.; Brugarolas, J.; McDonnell, T.J.; Golub, T.R. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10, 594-601.
165. Brugarolas, J.; Lei, K.; Hurley, R.L.; Manning, B.D.; Reiling, J.H.; Hafen, E.; Witters, L.A.; Ellisen, L.W.; Kaelin, W.G. Jr. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004, 18, 2893-2904.
166. Araki, K.; Turner, A.P.; Shaffer, V.O.; Gangappa, S.; Keller, S.A.; Bachmann, M.F.; Larsen, C.P.; Ahmed, R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460, 108-112.
167. He, S.; Kato, K.; Jiang, J.; Wahl, D.R.; Mineishi, S.; Fisher, E.M.; Murasko, D.M.; Glick, G.D.; Zhang, Y. Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells. PLoS One 2011, 6, e20107, doi:10.1371/journal.pone.0020107.
168. Pearce, E.L.; Walsh, M.C.; Cejas, P.J.; Harms, G.M.; Shen, H.; Wang, L.S.; Jones, R.G.; Choi, Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460, 103-107.
169. Hand, T.W.; Cui, W.; Jung, Y.W.; Sefik, E.; Joshi, N.S.; Chandele, A.; Liu, Y.; Kaech, S.M. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl. Acad. Sci. USA 2010, 107, 16601-16606.
170. Wang, Y.; Wang, X.Y.; Subjeck, J.R.; Shrikant, P.A.; Kim, H.L. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br. J. Cancer 2011, 104, 643-652.
171. Turner, A.P.; Shaffer, V.O.; Araki, K.; Martens, C.; Turner, P.L.; Gangappa, S.; Ford, M.L.; Ahmed, R.; Kirk, A.D.; Larsen, C.P. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am. J. Transplant. 2011, 11, 613-618.
172. El Essawy, B.; Putheti, P.; Gao, W.; Strom, T.B. Rapamycin generates graft-homing murine suppressor CD8(+) T cells that confer donor-specific graft protection. Cell Transplant. 2011, 20, 1759-1769.
173. Ferrer, I.R.; Wagener, M.E.; Robertson, J.M.; Turner, A.P.; Araki, K.; Ahmed, R.; Kirk, A.D.; Larsen, C.P.; Ford, M.L. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J. Immunol. 2010, 185, 2004-2008.
174. Zheng, Y.; Collins, S.L.; Lutz, M.A.; Allen, A.N.; Kole, T.P.; Zarek, P.E.; Powell, J.D. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J. Immunol. 2007, 178, 2163-2170.
175. Taner, T.; Hackstein, H.; Wang, Z.; Morelli, A.E.; Thomson, A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5, 228-236.
176. Reichardt, W.; Durr, C.; von Elverfeldt, D.; Juttner, E.; Gerlach, U.V.; Yamada, M.; Smith, B.; Negrin, R.S.; Zeiser, R. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J. Immunol. 2008, 181, 4770-4779.
177. Gabardi, S.; Baroletti, S.A. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010, 30, 1044-1056.
178. Dantal, J.; Berthoux, F.; Moal, M.C.; Rostaing, L.; Legendre, C.; Genin, R.; Toupance, O.; Moulin, B.; Merville, P.; Rerolle, J.P. et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-Month results of a randomized, multicenter trial. Transpl. Int. 2010, 23, 1084-1093.
179. Kahan, B.D. Fifteen years of clinical studies and clinical practice in renal transplantation: Reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Transpl. Proc. 2008, 40 (Suppl. 10), S17-S20.
180. Rosner, D.; McCarthy, N.; Bennett, M. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53. Cardiovasc. Res. 2005, 66, 601-610.
181. Sampson, J.R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem. Soc. Trans. 2009, 37, 259-264.
182. Hoogeveen, R.C.; Ballantyne, C.M.; Pownall, H.J.; Opekun, A.R.; Hachey, D.L.; Jaffe, J.S.; Oppermann, S.; Kahan, B.D.; Morrisett, J.D. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001, 72, 1244-1250.
183. Kahan, B.D.; Napoli, K.L.; Kelly, P.A.; Podbielski, J.; Hussein, I.; Urbauer, D.L.; Katz, S.H.; van Buren, C.T. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity. Clin. Transplant. 2000, 14, 97-109.
184. Chueh, S.C.; Kahan, B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 2003, 76, 375-382.
185. Kovarik, J.M.; Kaplan, B.; Tedesco Silva, H.; Kahan, B.D.; Dantal, J.; Vitko, S.; Boger, R.; Rordorf, C. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 2002, 73, 920-925.
186. McGaha, T.L.; Huang, L.; Lemos, H.; Metz, R.; Mautino, M.; Prendergast, G.C.; Mellor, A.L. Amino acid catabolism: A pivotal regulator of innate and adaptive immunity. Immunol. Rev. 2012, 249, 135-157.
187. Morrisett, J.D.; Abdel-Fattah, G.; Hoogeveen, R.; Mitchell, E.; Ballantyne, C.M.; Pownall, H.J.; Opekun, A.R.; Jaffe, J.S.; Oppermann, S.; Kahan, B.D. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J. Lipid Res. 2002, 43, 1170-1180.
188. Meiser, B.; Buchholz, S.; Kaczmarek, I. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-Year results. Curr. Opin. Organ Transplant. 2011, 16, 522-528.
189. Guertin, D.A.; Stevens, D.M.; Saitoh, M.; Kinkel, S.; Crosby, K.; Sheen, J.H.; Mullholland, D.J.; Magnuson, M.A.; Wu, H.; Sabatini, D.M. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15, 148-159.
190. Guertin, D.A.; Sabatini, D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2, pe24, doi:10.1126/scisignal.267pe24.
191. Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9-22.
192. Kordes, S.; Richel, D.J.; Klumpen, H.J.; Weterman, M.J.; Stevens, A.J.; Wilmink, J.W. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investig. New Drugs 2013, 31, 85-91.
193. Dong, M.; Phan, A.T.; Yao, J.C. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin. Cancer Res. 2012, 18, 1830-1836.
194. Dong, M.; Yao, J.C. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr. Relat. Cancer 2011, 18, C15-C18.
195. Peng, L.; Schwarz, R.E. Pancreatic neuroendocrine tumors: Signal pathways and targeted therapies. Curr. Mol. Med. 2013, 13, 333-339.
196. Huang, J.; Manning, B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 2009, 37, 217-222.